TP53 and neoplasm: In a larger BCa cohort, forty-six ribosomal sites (43.4%) exhibited high biological inter-patient variability, whereas a subset of four sites, namely 18S-Am576, 18S-Gm1447, 28S-Gm1303, and 28S-Gm4588, could discriminate between tumours with defined clinicopathological characteristics, e.g. tumour grade, tumour stage, hormonal and mutational (HER2, p53) status and BCa subtype.